Opinion: The breakthrough therapy designation for promising cancer drugs is good for patients

One exciting component of the was the creation of the breakthrough therapy designation. It allows an all-hands-on-deck approach at the FDA to determine the best path forward when the early clinical promise of a drug is so significant and meaningful beyond existing therapies — or lack of other meaningful therapies — for serious or life-threatening illnesses. Although the validity of the breakthrough designation was questioned recently in a tone-deaf article in the New England Journal of Medicine, this designation has provided